Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH 17-mediated autoimmune neuroinflammation

Nature Immunology

Volumn 14, Issue 11, 2013, Pages 1166-1172

  Garris, Christopher S ^a,b   Wu, Linfeng ^a   Acharya, Swati ^a   Arac, Ahmet ^a   Blaho, Victoria A ^c   Huang, Yingxiang ^a   Moon, Byoung San ^a   Axtell, Robert C ^a   Ho, Peggy P ^a   Steinberg, Gary K ^a   Lewis, David B ^a   Sobel, Raymond A ^a   Han, David K ^d   Steinman, Lawrence ^a   Snyder, Michael P ^a   Hla, Timothy ^c   Han, May H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; JANUS KINASE; PHOSPHOPROTEOME; PROTEOME; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL POLARITY; DISEASE EXACERBATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INTERNALIZATION; LYMPHOID ORGAN; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; RECEPTOR GENE; RELAPSE; S1PR1 GENE; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; TH17 CELL;

ANIMALS; AUTOPSY; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-6; JANUS KINASES; LYSOPHOSPHOLIPIDS; MICE; MULTIPLE SCLEROSIS; PHOSPHORYLATION; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; STAT3 TRANSCRIPTION FACTOR; TH17 CELLS;

EID: 84886721875     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2730     Document Type: Article

References (48)

1. Baumruker, T., Billich, A. Brinkmann, V. FTY720, an immunomodulatory sphingolipid mimetic: Translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin. Investig. Drugs 16, 283-289 (2007
2. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010
3. Cohen, J.A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010
4. Devonshire, V. et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 11, 420-428 (2012
5. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004
6. Chi, H. Flavell, R.A. Cutting edge: Regulation of T cell trafficking and primary immune responses by sphingosine 1-phosphate receptor 1. J. Immunol. 174, 2485-2488 (2005
7. Rosen, H. Goetzl, E.J. Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat. Rev. Immunol. 5, 560-570 (2005
8. Cyster, J.G., Schwab, S.R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69-94 (2012
9. Zhi, L. et al. FTY720 blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus. J. Immunol. 187, 2244-2251 (2011
10. Rivera, J., Proia, R.L., Olivera, A. The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753-763 (2008
11. Allende, M.L. et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279, 52487-52492 (2004
12. Halin, C. et al. The S1P-Analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood 106, 1314-1322 (2005
13. Oo, M.L. et al. Immunosuppressive and anti-Angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282, 9082-9089 (2007
14. Chun, J. Hartung, H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-101 (2010
15. Ingwersen, J. et al. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clin. Immunol. 142, 15-24 (2012
16. Cohen, J.A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010
17. Waubant, E. Emerging therapies for MS. Rev. Neurol. (Paris) 163, 688-696 (2007
18. Kieseier, B.C., Wiendl, H., Hemmer, B. Hartung, H.P. Treatment and treatment trials in multiple sclerosis. Curr. Opin. Neurol. 20, 286-293 (2007
19. Jander, S., Turowski, B., Kieseier, B.C., Hartung, H.P. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult. Scler. 18, 1650-1652 (2012
20. Bourdette, D. Gilden, D. Fingolimod and multiple sclerosis: Four cautionary tales. Neurology 79, 1942-1943 (2012
21. Visser, F., Wattjes, M.P., Pouwels, P.J., Linssen, W.H., van Oosten, B.W. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79, 2000-2003 (2012
22. Liu, C.H. et al. Ligand-induced trafficking of the sphingosine-1- phosphate receptor EDG-1. Mol. Biol. Cell 10, 1179-1190 (1999
23. Kohno, T. Igarashi, Y. N-glycosylation of sphingosine 1-phosphate receptor, Edg-1, and its role on receptor internalization through membrane microdomain. Tanpakushitsu Kakusan Koso 47, 503-508 (2002
24. Watterson, K.R. et al. Dual regulation of EDG1/S1P1 receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2. J. Biol. Chem. 277, 5767-5777 (2002
25. Thangada, S. et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J. Exp. Med. 207, 1475-1483 (2010
26. Oo, M.L. et al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J. Clin. Invest. 121, 2290-2300 (2011
27. Arnon, T.I. et al. GRK2-dependent S1P1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333, 1898-1903 (2011
28. Han, M.H. et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076-1081 (2008
29. Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002
30. Huttlin, E.L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-1189 (2010
31. Peng, J., Elias, J.E., Thoreen, C.C., Licklider, L.J., Gygi, S.P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: The yeast proteome. J. Proteome Res. 2, 43-50 (2003
32. Huang, W., Sherman, B.T., Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009
33. Huang, W., Sherman, B.T., Lempicki, R.A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009
34. Krebs, E.G., Kent, A.B., Fischer, E.H. The muscle phosphorylase b kinase reaction. J. Biol. Chem. 231, 73-83 (1958
35. Mayya, V., Rezual, K., Wu, L., Fong, M.B., Han, D.K. Absolute quantification of multisite phosphorylation by selective reaction monitoring mass spectrometry: Determination of inhibitory phosphorylation status of cyclin-dependent kinases. Mol. Cell Proteomics 5, 1146-1157 (2006
36. Chun, J. Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720, Gilenya). Discov. Med. 12, 213-228 (2011
37. Hla, T. Brinkmann, V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology 76, S3-S8 (2011
38. Loh, K.C. et al. Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS ONE 7, e37218 (2012
39. Rosen, H., Sanna, M.G., Cahalan, S.M., Gonzalez-Cabrera, P.J. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. 28, 102-107 (2007
40. Lovett-Racke, A.E., Yang, Y. Racke, M.K. Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis? Biochim. Biophys. Acta 1812, 246-251 (2011
41. Youssef, S. Steinman, L. At once harmful and beneficial: The dual properties of NF-κB. Nat. Immunol. 7, 901-902 (2006
42. Lee, M.J. et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279, 1552-1555 (1998
43. Schwab, S.R. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735-1739 (2005
44. Allende, M.L., Dreier, J.L., Mandala, S. Proia, R.L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem. 279, 15396-15401 (2004
45. Zhou, J. Saba, J.D. Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. Biochem. Biophys. Res. Commun. 242, 502-507 (1998
46. Lee, H. et al. STAT3-induced S1P1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 16, 1421-1428 (2010
47. Han, M.H. et al. Janus-like opposing roles of CD47 in autoimmune brain-inflammation in humans and mice. J. Exp. Med. 209, 1325-1334 (2012
48. Arac, A. et al. Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc. Natl. Acad. Sci. USA 108, 13287-13292 (2011